Study #2024-0342
A qualitative assessment of the severity and impact of rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy
MD Anderson Study Status
Enrolling
Treatment Agent
Description
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Arthritis;Polymyalgia Rheumatica;Immune Checkpoint Inhibitors
Study phase:
Physician name:
Yuanteng Jeff Li
Department:
General Internal Medicine
For general questions about clinical trials:
1-833-352-0464
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.